Bayer UK has unveiled a new Artificial Intelligence (AI) ‘LifeHub’ to optimise data-driven drug discovery and disease detection and diagnosis.
The company has launched LifeHub UK designed to accelerate and optimise disease detection and drug discovery by developing Artificial Intelligence enabled imaging solutions.
The Reading-based hub is the newest member of Bayer’s LifeHubs located in Berlin, Boston, California, Japan, Lyon and Singapore.
Kemal Malik, Bayer Board Member for Innovation, said “We are delighted to launch LifeHub UK. We firmly believe that Artificial Intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments.”
As a first step, LifeHub UK will focus on the development of AI-enabled radiology solutions. Clinical AI technology company, Sensyne Health, sealed a collaboration agreement with Bayer earlier this year and will be one of the first companies to have a presence in LifeHub UK.
Professor Dr. Olaf Weber, Head of Radiology R&D at Bayer “Bayer is looking forward to bringing its knowledge and expertise in medical imaging within radiology into joint development activities with our partners at LifeHub UK.”
Bayer has committed £3m and will be partnering with Sensyne Health to work on these novel projects. Rt Hon. Lord Drayson, CEO Sensyne Health Plc, said “Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research. I’m delighted to be working with Bayer, extending our partnership to deliver the benefits of digital innovation directly to clinicians and patients.”
The new hub is based in Reading’s Green Park, which includes more than 45,000 tech-related jobs and contributes around £12billion to UK annual digital technology revenues.
The LifeHub UK partners are: Sensyne Health in Oxford and Reading University, Royal Berkshire Hospital and Harwell Science & Innovation Campus.
Dr Diana Medeiros Placido, head of LifeHub UK, said “The UK is the place to be in the Global tech ecosystem and we are excited to strengthen our presence here, connecting with some of the brightest minds to jointly explore, discover and develop leading customer-centric solutions to advance patient care.”
